The Experts below are selected from a list of 27 Experts worldwide ranked by ideXlab platform
Laurent Morin - One of the best experts on this subject based on the ideXlab platform.
-
Feasibility and benefits of an innovative Airway Clearance Device in COPD patients hospitalized for acute exacerbation
Rehabilitation and chronic care, 2020Co-Authors: Ivan Solovic, Alena Bodnarova, Laurent MorinAbstract:Introduction: Airway Clearance Devices (ACDs) may improve symptoms and lung function in Chronic Obstructive Pulmonary Disease (COPD) with mucus hyperproduction or bronchiectasis but innovation needs to be evaluated. Aim: Aim of study was to assess feasibility and effects of a new ACD in hospitalized COPD patients suffering from chest congestion despite optimal medical treatment. Methods: 32 patients with AECOPD and symptoms of excessive mucus congestion were treated during 6 days with medical treatment, pulmonary rehabilitation and Airway Clearance with either manual chest physiotherapy (control; n=13) or new ACD (Simeox, Physio-Assist; n=19) that facilitates bronchial drainage by generating pulses of negative air pressure during relaxed exhalations. Usability, spirometry, CAT score, safety and tolerance were evaluated. Results: Baseline: age 67.3 6.7, 69% male, GOLD 2/3/4: 19%/31%/50%, GOLD B/C/D: 3%/19%/78%, 31% bronchiectasis (BE), 66% had ICS/LABA/LAMA, CAT score 29.0±3.3. Patient training required 15 min during the first session. No adverse event nor pain was reported. FEV1 increased by 19±10% and 14±5% in Device and control group (NS), respectively. However, improvement of CAT score was higher in Device group (-34±9% vs control: -24±4%; p Conclusion: These results confirmed the feasibility of this new technology to manage mucus problems in COPD and suggested that it may contribute to improve respiratory symptoms and quality of life in the most severe patients
-
physiological effects of simeox Airway Clearance Device in healthy adults
European Respiratory Journal, 2020Co-Authors: Laurent Morin, Damien Marino, Adrien MithalalAbstract:Introduction: Airway Clearance Devices (ACDs) assist in mobilizing retained secretions in lung diseases by increasing the velocity of expiratory flow. Aim: Aim of this study was to characterize oscillatory flow and negative expiratory pressure pulses generated by a new ACD in healthy subjects. Methods: 10 healthy adults activated a Device (Simeox, PhysioAssist) generating intermittent pulses of intrapulmonary negative air pressure during relaxed exhalations. The procedure was repeated twice with 4 settings (25% or 100% power at 6 or 12 Hz frequency). Oscillatory flow and pressure pulses were measured at the mouth with a flow sensor (TSI, Certifier FA plus) to assess Maximal expiratory flow (MEF), maximal mid-expiratory flow (MMEF), Mean expiratory flow (EFmean), maximal expiratory flow amplitude (MEFamp), peak of negative expiratory pressure (NEPpeak) and maximal expiratory pressure amplitude (MEPamp). Results: 60% male, 34±12y, FEV1/FVC 90±14%. Data are presented in table 1. MEF (60 to 120 l/min) and MEFamp (70 to140 l/min) rates supported generation of high airflow velocity during exhalation over power range. Oscillatory flow was maintained at mid-exhalation. Low variability of data showed high reproducibility of flow and negative pressure pulses generated with Simeox during procedure. Range of pressure was safe (-10 to -60 mbar). Conclusions: These data suggest that Simeox may be an efficient and secure technology for Airway Clearance therapy.
Adrien Mithalal - One of the best experts on this subject based on the ideXlab platform.
-
physiological effects of simeox Airway Clearance Device in healthy adults
European Respiratory Journal, 2020Co-Authors: Laurent Morin, Damien Marino, Adrien MithalalAbstract:Introduction: Airway Clearance Devices (ACDs) assist in mobilizing retained secretions in lung diseases by increasing the velocity of expiratory flow. Aim: Aim of this study was to characterize oscillatory flow and negative expiratory pressure pulses generated by a new ACD in healthy subjects. Methods: 10 healthy adults activated a Device (Simeox, PhysioAssist) generating intermittent pulses of intrapulmonary negative air pressure during relaxed exhalations. The procedure was repeated twice with 4 settings (25% or 100% power at 6 or 12 Hz frequency). Oscillatory flow and pressure pulses were measured at the mouth with a flow sensor (TSI, Certifier FA plus) to assess Maximal expiratory flow (MEF), maximal mid-expiratory flow (MMEF), Mean expiratory flow (EFmean), maximal expiratory flow amplitude (MEFamp), peak of negative expiratory pressure (NEPpeak) and maximal expiratory pressure amplitude (MEPamp). Results: 60% male, 34±12y, FEV1/FVC 90±14%. Data are presented in table 1. MEF (60 to 120 l/min) and MEFamp (70 to140 l/min) rates supported generation of high airflow velocity during exhalation over power range. Oscillatory flow was maintained at mid-exhalation. Low variability of data showed high reproducibility of flow and negative pressure pulses generated with Simeox during procedure. Range of pressure was safe (-10 to -60 mbar). Conclusions: These data suggest that Simeox may be an efficient and secure technology for Airway Clearance therapy.
Damien Marino - One of the best experts on this subject based on the ideXlab platform.
-
physiological effects of simeox Airway Clearance Device in healthy adults
European Respiratory Journal, 2020Co-Authors: Laurent Morin, Damien Marino, Adrien MithalalAbstract:Introduction: Airway Clearance Devices (ACDs) assist in mobilizing retained secretions in lung diseases by increasing the velocity of expiratory flow. Aim: Aim of this study was to characterize oscillatory flow and negative expiratory pressure pulses generated by a new ACD in healthy subjects. Methods: 10 healthy adults activated a Device (Simeox, PhysioAssist) generating intermittent pulses of intrapulmonary negative air pressure during relaxed exhalations. The procedure was repeated twice with 4 settings (25% or 100% power at 6 or 12 Hz frequency). Oscillatory flow and pressure pulses were measured at the mouth with a flow sensor (TSI, Certifier FA plus) to assess Maximal expiratory flow (MEF), maximal mid-expiratory flow (MMEF), Mean expiratory flow (EFmean), maximal expiratory flow amplitude (MEFamp), peak of negative expiratory pressure (NEPpeak) and maximal expiratory pressure amplitude (MEPamp). Results: 60% male, 34±12y, FEV1/FVC 90±14%. Data are presented in table 1. MEF (60 to 120 l/min) and MEFamp (70 to140 l/min) rates supported generation of high airflow velocity during exhalation over power range. Oscillatory flow was maintained at mid-exhalation. Low variability of data showed high reproducibility of flow and negative pressure pulses generated with Simeox during procedure. Range of pressure was safe (-10 to -60 mbar). Conclusions: These data suggest that Simeox may be an efficient and secure technology for Airway Clearance therapy.
Dorota Sands - One of the best experts on this subject based on the ideXlab platform.
-
the effects of the addition of a new Airway Clearance Device to chest physiotherapy in children with cystic fibrosis pulmonary exacerbations
Journal of mother and child, 2021Co-Authors: Katarzyna Walickaserzysko, M Postek, Natalia Jeneralska, Aleksandra Cichocka, Justyna Milczewska, Dorota SandsAbstract:BACKGROUND Chest physiotherapy plays a crucial role in managing cystic fibrosis, especially during pulmonary exacerbations. This study evaluated the effects of adding a new Airway Clearance Device to chest physiotherapy in subjects with cystic fibrosis hospitalised due to pulmonary exacerbations. METHODS This prospective open-label study was carried out at the Pediatric Cystic Fibrosis Centre in Poland between October 2017 and August 2018. Cystic fibrosis patients aged 10 to 18 years who were admitted to the hospital and required intravenous antibiotic therapy due to pulmonary exacerbations were consecutively allocated (1:1) to either chest physiotherapy alone or chest physiotherapy with a new Airway Clearance Device (Simeox; PhysioAssist). Patients performed spirometry and multiple-breath nitrogen washout for lung Clearance index assessment upon admission and prior to discharge. RESULTS Forty-eight cystic fibrosis patients were included (24 in each group). Spirometry parameters in both groups improved significantly after intravenous antibiotic therapy. A significant improvement in the maximum expiratory flow at 25% of forced vital capacity was observed only in the group with a new Airway Clearance Device (p < 0.01 vs. baseline). Trends towards a lower lung Clearance index ratio were similar in both groups. No adverse events were observed in either group. CONCLUSIONS Spirometry parameters increased significantly in cystic fibrosis patients treated for pulmonary exacerbations with intravenous antibiotic therapy and intensive chest physiotherapy. The new Airway Clearance Device was safe and well tolerated when added to chest physiotherapy and may be another option for the treatment of pulmonary exacerbation in cystic fibrosis.
Sue Palmer Hill - One of the best experts on this subject based on the ideXlab platform.
-
evaluation of dechoker an Airway Clearance Device acd used in adult choking emergencies within the adult care home sector a mixed methods case study
Frontiers in Public Health, 2020Co-Authors: Bhavik G Bhanderi, Sue Palmer HillAbstract:Foreign Body Airway Obstruction (FBAO) is a medical emergency that can result in death, particularly if swift, appropriate action is not taken. It can be a frightening experience for all involved. DeChoker, an Airway Clearance Device (ACD), might provide an additional alternative in the management of choking; however, limited evidence around its safety and effectiveness makes adoption controversial. Objectives: An independent evaluation to explore the experiences of health and care professionals who used DeChoker in real-life adult choking emergencies, focusing on the product's safety, efficacy and ease of application. Design: Retrospective mixed methods case study, with multiple embedded units of analysis. Setting: UK adult care homes. Participants: Twenty seven incidents of adult choking emergencies self-reported by care home staff where DeChoker was used. This data was augmented by an in-depth exploration of four individual choking incidences. Results: The choking victim's ages range: 45 to 101 years (mean 79.8 years). The Device was reported to have successfully removed the obstruction in 26 of 27 cases, with very few complications or adverse events reported. In 21 of 27 incidents (78%) the victim was not required to visit Accident and Emergency. Qualitative data indicated nursing home staff found the DeChoker easy to use and valued its presence as an adjunct to current guideline procedures. Conclusion: There is a dearth of evidence surrounding the management of choking and little innovation in this area for five decades. This retrospective evaluation contributes to discussion regarding the role ACDs might play in the management of choking, particularly in cases where current choking management guidance are ineffective, insufficient, inappropriate or impractical (e.g., frail or movement restricted people). The interview data presents a view from care home staff that the DeChoker, as an ACD, contributed to saving the life of choking victims.